bcg vaccine

Summary

Summary: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.

Top Publications

  1. pmc Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update
    Madhukar Pai
    McGill University and Montreal Chest Institute, Montreal, Quebec, Canada
    Ann Intern Med 149:177-84. 2008
  2. ncbi Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness
    B Bourdin Trunz
    Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 367:1173-80. 2006
  3. pmc Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation
    Kaeryn N Lewis
    Department of Pediatrics, University of Washington, Seattle 98195, USA
    J Infect Dis 187:117-23. 2003
  4. ncbi Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
    Alexander S Pym
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Mol Microbiol 46:709-17. 2002
  5. ncbi The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children
    Anneke C Hesseling
    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, P O Box 19063, Tygerberg, 7505, South Africa
    Vaccine 25:14-8. 2007
  6. pmc Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:1073-9. 2010
  7. ncbi False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?
    M Farhat
    Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
    Int J Tuberc Lung Dis 10:1192-204. 2006
  8. ncbi Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
  9. pmc Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
    Leander Grode
    Max Planck Institute for Infection Biology, Berlin, Germany
    J Clin Invest 115:2472-9. 2005
  10. ncbi Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes
    Valérie Abadie
    Mycobacterial Genetics Unit, Institut Pasteur, 25 rue du Docteur Roux, 7724 Paris Cedex 15, France
    Blood 106:1843-50. 2005

Detail Information

Publications285 found, 100 shown here

  1. pmc Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update
    Madhukar Pai
    McGill University and Montreal Chest Institute, Montreal, Quebec, Canada
    Ann Intern Med 149:177-84. 2008
    ..A recent meta-analysis showed that IGRAs have high specificity, even among populations that have received bacille Calmette-Guérin (BCG) vaccination. Sensitivity was suboptimal for TST and IGRAs...
  2. ncbi Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness
    B Bourdin Trunz
    Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 367:1173-80. 2006
    b>BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases...
  3. pmc Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation
    Kaeryn N Lewis
    Department of Pediatrics, University of Washington, Seattle 98195, USA
    J Infect Dis 187:117-23. 2003
    ..Therefore, it was concluded that genes within or controlled by RD1 are essential for MTB virulence and that loss of RD1 was important in BCG attenuation...
  4. ncbi Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
    Alexander S Pym
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Mol Microbiol 46:709-17. 2002
    ..Knocking-in five other RD loci did not affect the virulence of BCG. This study describes a genetic lesion that contributes to safety and opens new avenues for vaccine development...
  5. ncbi The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children
    Anneke C Hesseling
    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, P O Box 19063, Tygerberg, 7505, South Africa
    Vaccine 25:14-8. 2007
    ..We estimate the risk of disseminated BCG disease in HIV-infected children in a setting highly endemic for tuberculosis and HIV...
  6. pmc Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
    Benjamin M N Kagina
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 182:1073-9. 2010
    ..Immunogenicity of new tuberculosis (TB) vaccines is commonly assessed by measuring the frequency and cytokine expression profile of T cells...
  7. ncbi False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?
    M Farhat
    Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
    Int J Tuberc Lung Dis 10:1192-204. 2006
    ..However, TST specificity is reduced by bacille Calmette-Guérin (BCG) vaccination and exposure to non-tuberculous mycobacteria (NTM)...
  8. ncbi Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
    ..We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer...
  9. pmc Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
    Leander Grode
    Max Planck Institute for Infection Biology, Berlin, Germany
    J Clin Invest 115:2472-9. 2005
    ..We concluded that superior vaccine efficacy of DeltaureC hly+ rBCG as compared with parental BCG is primarily based on improved cross-priming, which causes enhanced T cell-mediated immunity...
  10. ncbi Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes
    Valérie Abadie
    Mycobacterial Genetics Unit, Institut Pasteur, 25 rue du Docteur Roux, 7724 Paris Cedex 15, France
    Blood 106:1843-50. 2005
    ..Thus, we provide in vivo evidence that neutrophils, like DCs or inflammatory monocytes, migrate via afferent lymphatics to lymphoid tissue and can shuttle live microorganisms...
  11. pmc Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis
    Kristi M Guinn
    Department of Pathobiology, University of Washington, Seattle, WA 98195, USA
    Mol Microbiol 51:359-70. 2004
    ..Our results indicate that RD1 genes work together to form a single virulence determinant, and argue that RD1 encodes a novel specialized secretion system that is required for pathogenesis of MTB...
  12. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
    Tony Hawkridge
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    J Infect Dis 198:544-52. 2008
    ..We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic...
  13. pmc Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis
    Hans Willi Mittrücker
    Department of Immunology, Max Planck Institute for Infection Biology, Caritéplatz 1, 10117 Berlin, Germany
    Proc Natl Acad Sci U S A 104:12434-9. 2007
    ..tuberculosis rather than the strength of protection. Our data question the measurement of IFN-gamma secretion by CD4(+) T cells and emphasize the need for new biomarkers for evaluation of tuberculosis vaccine efficacies...
  14. pmc Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis
    Andrea Cruz
    Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710 057 Braga, Portugal
    J Exp Med 207:1609-16. 2010
    ..This finding that repeated exposure to mycobacterial antigen promotes enhanced IL-17-dependent pathological consequences has important implications for the design of effective vaccines against Mtb...
  15. ncbi Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
    J L Flynn
    Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA
    Immunity 2:561-72. 1995
    ..TNF alpha and the 55 kDa TNF receptor are necessary conditions for protection against murine M. tuberculosis infection, but are not solely responsible for the tissue damage observed...
  16. ncbi Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
    Jaap T van Dissel
    Leiden University Medical Center, Department of Infectious Diseases, Leiden, The Netherlands
    Vaccine 28:3571-81. 2010
    Though widely used, the BCG vaccine has had little apparent effect on rates of adult pulmonary tuberculosis...
  17. ncbi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
    ..Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs...
  18. pmc MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques
    Frank A W Verreck
    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
    PLoS ONE 4:e5264. 2009
    ..Relevant models are required to downselect the most promising vaccines entering clinical efficacy testing and to identify correlates of protection...
  19. ncbi Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis
    Daniel Elias
    Microbiology and Tumor Biology Center, Karolinska Institute, Box 280, 17177 Stockholm, Sweden
    Vaccine 23:1326-34. 2005
    ..tuberculosis possibly by attenuation of protective immune responses to mycobacterial antigens and/or by polarizing the general immune responses to the Th2 profile...
  20. ncbi Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara
    Nilu P Goonetilleke
    Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:1602-9. 2003
    ..These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis...
  21. pmc Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination
    B M Buddle
    AgResearch, Wallaceville Animal Research Centre, Upper Hutt, New Zealand
    Infect Immun 71:6411-9. 2003
    ..However, BCG revaccination of these young animals was contraindicated...
  22. pmc Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice
    Bo Young Jeon
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 76:5173-80. 2008
    ..tuberculosis genotypes (in particular, Beijing lineage strains) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis protective immunity...
  23. ncbi A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Building 29, Room 502, CBER FDA, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Vaccine 23:780-8. 2004
    ....
  24. pmc Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis
    Diane Ordway
    Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523 1682, USA
    Clin Vaccine Immunol 15:1248-58. 2008
    ....
  25. pmc Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis
    H Martin Vordermeier
    Veterinary Laboratories Agency Weybridge, TB Research Group, New Haw, Addlestone, Surrey KT15 3NB, United Kingdom
    Infect Immun 70:3026-32. 2002
    ....
  26. pmc IL-23 and IL-17 in tuberculosis
    Shabaana A Khader
    Trudeau Institute, Inc, 154 Algonquin Ave, Saranac Lake, NY 12983, USA
    Cytokine 41:79-83. 2008
    ..Th1 and Th17 responses cross-regulate each other during mycobacterial infection and this may be important for immunopathologic consequences not only in tuberculosis but also other mycobacterial infections...
  27. pmc Assessment of immunity to mycobacterial infection with luciferase reporter constructs
    V A Snewin
    Department of Infectious Diseases and Microbiology, Imperial College School of Medicine, St Mary s Campus, London W2 1PG, United Kingdom
    Infect Immun 67:4586-93. 1999
    ....
  28. ncbi Future vaccination strategies against tuberculosis: thinking outside the box
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Chariteplatz 1, D 10117 Berlin, Germany
    Immunity 33:567-77. 2010
    ..Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future...
  29. ncbi The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial
    Nicole Ritz
    Department of Paediatrics, The University of Melbourne, Parkville, Vic, Australia
    Am J Respir Crit Care Med 185:213-22. 2012
    ..More than 20 genetically distinct BCG vaccine strains are in use worldwide...
  30. ncbi Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study
    Ahmet Soysal
    Department of Paediatrics, Marmara University School of Medicine, Istanbul, Turkey
    Lancet 366:1443-51. 2005
    ....
  31. ncbi Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial
    Leander Grode
    Vakzine Projekt Management GmbH, Hannover, Germany
    Vaccine 31:1340-8. 2013
    ..New vaccination strategies are essential for reducing the global incidence of TB. We assessed the safety and immunogenicity of VPM1002, a recombinant BCG vaccine candidate. EudraCT (2007-002789-37) and ClinicalTrials.gov (NCT00749034).
  32. pmc Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 Ligandhi population
    Andre Kipnis
    Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
    Infect Immun 73:7759-64. 2005
    ..Upon cell transfer, however, cells expressing a resting/naïve phenotype (CD44lo CD62Lhi) were capable of protecting the recipients from a virulent challenge infection, suggesting the emergence of T-cell memory from within this subset...
  33. pmc Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations
    Shu Zhang
    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
    Clin Vaccine Immunol 17:1985-90. 2010
    ..Furthermore, the T-SPOT.TB assay using ESAT-6 and CFP-10 in ATB patients during anti-TB treatment could serve as a potential predictor of therapeutic efficacy...
  34. ncbi Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis
    Ronggai Sun
    Aeras Global TB Vaccine Foundation, 1405 Research Blvd, Rockville, MD 20850, USA
    Vaccine 27:4412-23. 2009
    ..Thus, we have generated improved rBCG vaccine candidates that address many of the shortcomings of the currently licensed BCG vaccine strains.
  35. ncbi Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age
    Sarah Burl
    Medical Research Council United Kingdom, The Gambia, Fajara, The Gambia, West Africa
    J Immunol 185:2620-8. 2010
    ..results at 4 1/2 mo postvaccination revealed lower IFN-gamma, IL-6, and IL-17 responses in the delayed BCG vaccine group compared with those vaccinated at birth, but this did not relate to Treg levels prevaccination...
  36. pmc Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis
    Lihao Chen
    Infectious Diseases Division, Center for Gene Therapeutics, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    Infect Immun 72:238-46. 2004
    ..c. vaccinated counterparts against pulmonary tuberculosis at both 3 and 6 months postvaccination. These results suggest that the i.n. route of vaccination improves the protective effect of the current BCG vaccine.
  37. pmc Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
    Elma Z Tchilian
    The Jenner Institute, Oxford University, ORCRB, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Infect Immun 77:622-31. 2009
    ..candidates are the recombinant DeltaureC hly(+) BCG (recBCG), which has been developed to replace the current BCG vaccine strain, and modified vaccinia virus Ankara (MVA) expressing M...
  38. ncbi Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guérin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains
    Masaaki Seki
    Japan BCG Laboratory, Research of Product, 3 1 5 Matsuyama, Kiyose City, Tokyo 204 0022, Japan
    Vaccine 27:1710-6. 2009
    ..These findings are useful for better understanding of the genetic differences in BCG substrains due to in vitro evolution of BCG...
  39. pmc Boosting vaccine for tuberculosis
    J V Brooks
    Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado 80523, USA
    Infect Immun 69:2714-7. 2001
    ....
  40. ncbi The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination
    Christine Stabell Benn
    Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark
    Vaccine 27:2891-8. 2009
    ..effect on mortality in a randomised trial of vitamin A supplementation (VAS) or placebo administered with BCG vaccine at birth in Guinea-Bissau...
  41. ncbi Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia
    Christian Lienhardt
    IRD, BP 1386, Dakar, Senegal
    Am J Respir Crit Care Med 168:448-55. 2003
    ....
  42. ncbi Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection
    E Jouanguy
    INSERM Unité 429, Hopital Necker Enfants Malades, Paris, France
    N Engl J Med 335:1956-61. 1996
  43. pmc Genome plasticity of BCG and impact on vaccine efficacy
    Roland Brosch
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 104:5596-601. 2007
    ..Furthermore, the combined findings suggest that early BCG vaccines may even be superior to the later ones that are more widely used...
  44. pmc Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung
    Ruchi Jain
    Department of Biochemistry, University of Delhi South Campus, New Delhi, India
    PLoS ONE 3:e3869. 2008
    ..Development of recombinant BCG (rBCG) over-expressing promising immunodominant antigens of M. tuberculosis represents one of the potential approaches for the development of vaccines against TB...
  45. pmc Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles
    Andreia P Soares
    South African TB Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    J Immunol 180:3569-77. 2008
    ..Measuring IFN-gamma production alone underestimates the magnitude and complexity of the host cytokine response to BCG vaccination and may not be an optimal readout in studies of BCG and novel tuberculosis vaccination...
  46. ncbi Does the efficacy of BCG decline with time since vaccination?
    J A Sterne
    Department of Public Health Medicine, United Medical and Dental Schools, St Thomas s Hospital, London, UK
    Int J Tuberc Lung Dis 2:200-7. 1998
    ..To investigate whether the protective efficacy of bacille Calmette-Guérin (BCG) against tuberculosis decreases with time since vaccination...
  47. pmc Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice
    Emily K Forbes
    The Jenner Institute, University of Oxford, Headington, Oxford, United Kingdom
    J Immunol 181:4955-64. 2008
    ..Successful immunization regimes appear to induce Ag-specific cells with abundant intracellular cytokine staining...
  48. ncbi How can immunology contribute to the control of tuberculosis?
    S H Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
    Nat Rev Immunol 1:20-30. 2001
    ..tuberculosis will be vital in the design of a future vaccine...
  49. ncbi An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer
    Per Uno Malmstrom
    Uppsala University Hospital, Department of Urology, Uppsala, Sweden
    Eur Urol 56:247-56. 2009
    ..Individual patient data (IPD) meta-analyses, however, are the gold standard...
  50. pmc Tuberculosis: what we don't know can, and does, hurt us
    David G Russell
    Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Science 328:852-6. 2010
    ..Here we focus on the biology of the host-pathogen interaction and discuss new and evolving strategies for intervention...
  51. pmc Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial
    Christine Stabell Benn
    Bandim Health Project, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
    BMJ 336:1416-20. 2008
    To investigate the effect of high dose vitamin A supplementation given with BCG vaccine at birth in an African setting with high infant mortality.
  52. pmc Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns
    Andreia P Soares
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 207:1084-94. 2013
    ..Furthermore, the functional and phenotypic attributes of BCG-induced long-lived memory T-cell responses remain unclear...
  53. ncbi BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control
    Corinne S C Merle
    Department of Epidemiology and Population Health, Tropical Epidemiological Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Expert Rev Vaccines 9:209-22. 2010
    ..In the light of the results, we argue for more emphasis on the role of BCG vaccination in leprosy control and research...
  54. ncbi BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model
    Elizabeth C De Boer
    Department of Urology, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur Urol 48:333-8. 2005
    ....
  55. ncbi IL-4 in tuberculosis: implications for vaccine design
    Graham A W Rook
    Centre for Infectious Diseases and International Health, Windeyer Institute for Medical Sciences, Royal Free and University College Medical School, 46 Cleveland Street, London, UK
    Trends Immunol 25:483-8. 2004
    ..If this is important, effective vaccines will need to suppress pre-existing Th2-like activity. Such vaccines are feasible and are active therapeutically in mouse TB...
  56. ncbi Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea-Bissau 2000-2002
    Adam Roth
    Bandim Health Project, Apartado 861, Bissau, Guinea Bissau
    Vaccine 23:3991-8. 2005
    ..Three different types of BCG vaccine supplied by the local Extended Programme on Immunization were used...
  57. ncbi Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
    Rui Fa Han
    Tianjin Institute of Urologic Surgery, Tianjin, China
    Urology 67:1216-23. 2006
    ..To determine whether intravesical bacillus Calmette-Guérin (BCG) administration reduces recurrence after transurethral resection of superficial bladder cancer using a meta-analysis...
  58. ncbi Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection
    Anthony A Ryan
    Microbial Pathogenesis and Immunity Group, Discipline of Infectious Diseases
    J Immunol 182:7172-7. 2009
    ..However, the relative capacity of the BCG vaccine and virulent Mycobacterium tuberculosis to induce activation of CD8 T cells, and the factors that govern the ..
  59. ncbi Vaccination of the brushtail possum (Trichosurus vulpecula) against Mycobacterium bovis infection with bacille Calmette-Guérin: the response to multiple doses
    L A L Corner
    Epicentre, Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Private Bag 11 222, Palmerston North, New Zealand
    Vet Microbiol 84:327-36. 2002
    ..It was concluded that protection would be enhanced if vaccinations were repeated at short intervals (weekly), but no benefit or detriment resulted from revaccination after longer intervals (1-2 months)...
  60. ncbi Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A
    S M Smith
    Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom
    J Immunol 165:7088-95. 2000
    ..These results demonstrate a previously unrecognized, MHC class I-restricted, CD8(+) CTL response to a major secreted Ag of mycobacteria and supports the use of Ag85A as a candidate vaccine against tuberculosis...
  61. ncbi Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial
    Mauricio L Barreto
    Instituto De Saude Coletiva, Universidade Federal da Bahia, Rua Padre Feijó, 29, 40 110 179 Salvador, Brazil
    Vaccine 29:4875-7. 2011
    ..The findings are in line with the hypothesis that BCG vaccination offers higher efficacy in low NTMb prevalence, and show that revaccination with BCG can offer weak protection in selected subgroups...
  62. ncbi The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables
    Jesus Fernandez-Gomez
    Department of Urology, Hospital Central of Asturias, University of Oviedo, Oviedo, Spain
    Eur Urol 60:423-30. 2011
    ..European Organization for Research and Treatment of Cancer (EORTC) risk tables only included 171 patients treated with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC)...
  63. ncbi An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time
    Marta Romano
    Scientific Institute of Public Health WIV ISP Site Ukkel, Program Host Pathogen Interactions, Service Immunology, Brussels, Belgium
    Expert Opin Biol Ther 12:1601-10. 2012
    ..Apart from better diagnostics and new anti-microbial drugs, an effective vaccine for tuberculosis is urgently needed to halt this poverty-related disease, afflicting millions of people worldwide...
  64. pmc Bacillus Calmette-Guérin vaccination using a microneedle patch
    Yasuhiro Hiraishi
    School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 311 Ferst Drive, N W, Atlanta, GA 30332, USA
    Vaccine 29:2626-36. 2011
    ....
  65. pmc Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth
    S Worku
    Department of Internal Medicine, Saint Louis University Center for Vaccine Development, St Louis, MO 63110, USA
    Infect Immun 71:1763-73. 2003
    ..These culture systems provide in vitro models for studying the opposing T-cell mechanisms involved in mycobacterial survival and protective host immunity...
  66. ncbi Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance
    Jorg Oddens
    Department of Urology, Jeroen Bosch Ziekenhuis, s Hertogenbosch, The Netherlands
    Eur Urol 63:462-72. 2013
    ..The optimal dose and duration of intravesical bacillus Calmette-Guérin (BCG) in the treatment of non-muscle-invasive bladder cancer (NMIBC) are controversial...
  67. pmc Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice
    Elihu Aranday Cortes
    TB Research Group, Veterinary Laboratories Agency, Addlestone, United Kingdom
    PLoS ONE 5:e11319. 2010
    ..bovis. Further, these biosignatures should be detectable without in vitro antigenic challenge...
  68. pmc Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial
    Christine Stabell Benn
    Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark
    BMJ 340:c1101. 2010
    ..To investigate the effect of vitamin A supplementation and BCG vaccination at birth in low birthweight neonates...
  69. ncbi Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer
    Shiro Hinotsu
    Kyoto University, Kyoto, Japan
    BJU Int 108:187-95. 2011
    ..To confirm the recurrence-preventing efficacy and safety of 18-month bacillus Calmette-Guérin (BCG) maintenance therapy for non-muscle-invasive bladder cancer...
  70. ncbi Beyond BCG: the potential for a more effective TB vaccine
    I M Orme
    Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, CO 80523, USA
    Mol Med Today 5:487-92. 1999
    ..The real difficulty will probably arise at the clinical trial level, when a decision must be made either to replace BCG or to boost existing BCG-induced immunity using these new-generation vaccines...
  71. pmc Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death
    Adriana Aporta
    Grupo Apoptosis, Inmunidad y Cáncer, Dpto Bioquímica y Biología Molecular y Celular, Fac Ciencias, Universidad de Zaragoza, Zaragoza, Spain
    PLoS ONE 7:e45213. 2012
    ..tuberculosis infection...
  72. pmc A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses
    Yenny Djuardi
    Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
    PLoS ONE 5:e14066. 2010
    b>BCG vaccine drives a strong T helper 1 cellular immunity which is essential for the protection against mycobacteria, however recent studies suggest that BCG vaccination can have non-specific beneficial effects unrelated to tuberculosis...
  73. pmc Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer
    Meng Chen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 3:1235-45. 2010
    ..05), none remained significant after multiple-comparison adjustments. Germ-line genetic variations in the Shh pathway predicted clinical outcomes of TUR and BCG for NMIBC patients...
  74. ncbi Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors
    J Palou
    Department of Urology, , , Barcelona, Spain
    J Urol 165:1488-91. 2001
    ..CONCLUSIONS: Six-month maintenance therapy in patients treated initially for carcinoma in situ and/or high grade superficial bladder tumors who are disease-free at 6 months did not significantly decrease recurrence or progression...
  75. ncbi Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study
    Takahiro Yoneyama
    Department of Urology, Hirosaki University of Medicine, Hirosaki, Japan
    Urology 71:1161-5. 2008
    ..To evaluate the effectiveness and side effects of prophylactic low-dose bacille Calmette-Guérin (BCG) Tokyo 172 strain...
  76. ncbi Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence
    Akira Irie
    Department of Urology, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara, Kanagawa 228 8555, Japan
    Int J Urol 10:183-9. 2003
    ..Adverse effects of BCG are major obstacles, but the reduction of BCG dose could minimize these effects. The efficacy and adverse effects of half-dose (40 mg) BCG, Tokyo 172 strain, were prospectively evaluated...
  77. pmc BCG-mediated protection against Mycobacterium ulcerans infection in the mouse
    Paul J Converse
    Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA
    PLoS Negl Trop Dis 5:e985. 2011
    ..In mice, most studies use the C57BL/6 strain that is known to develop good cell-mediated protective immunity. We hypothesized that there may be differences in vaccination efficacy between C57BL/6 and the less resistant BALB/c strain...
  78. ncbi Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis
    Bryce M Buddle
    AgResearch, Wallaceville Animal Research Centre, P O Box 40063, Upper Hutt, New Zealand
    Vaccine 23:3581-9. 2005
    ..Oral vaccination of BCG in a lipid-formulation to calves was shown to induce some positive tuberculin skin test reactions, but could also induce protection against bovine tuberculosis...
  79. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...
  80. pmc A critical role for CD8 T cells in a nonhuman primate model of tuberculosis
    Crystal Y Chen
    Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, Illinois, USA
    PLoS Pathog 5:e1000392. 2009
    ..tuberculosis-elicited CD8 T cells to vaccine-induced immunity against tuberculosis. CD8 depletion compromised BCG vaccine-induced immune control of M. tuberculosis replication in the vaccinated rhesus macaques...
  81. ncbi Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis
    M Haile
    Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna, Sweden
    Vaccine 22:1498-508. 2004
    ..vaccine given in a new adjuvant (Eurocine L3) with the protection provided by the conventional live attenuated BCG vaccine in mice (C57BL/6 and BALB/c) challenged with virulent Mycobacterium tuberculosis (strain Harlingen)...
  82. ncbi Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors
    Richard Hopkins
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 41:3542-52. 2011
    ..These results encourage further development of the rBCG prime-boost regimen...
  83. pmc Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis
    Mark A Chambers
    TB Research Group, Department of Bacterial Diseases, Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey, KT15 3NB, United Kingdom
    Infect Immun 70:2159-65. 2002
    ..In contrast, vaccination with antigen 85A DNA, a promising DNA vaccine for human tuberculosis, had no measurable protective effect against infection with M. bovis...
  84. ncbi The immune response to BCG vaccination of newborns
    Willem A Hanekom
    SATVI, Institute of Infectious Diseases and Molecular Medicine, UCT Health Sciences Faculty, Wernher and Beit S2 01, Anzio Road, Observatory, 7925 Cape Town, South
    Ann N Y Acad Sci 1062:69-78. 2005
    ..Tests will, therefore, be made to determine whether CD8 or regulatory CD4 T-cell responses, as well as "outlier" cytokine responses, are associated with vaccination-induced protection against tuberculosis...
  85. ncbi Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination
    David K Flaherty
    Department of Internal Medicine, Division of Infectious Diseases, Center for Microbial Interface Biology, 420 West 12th Avenue, Columbus, OH 43210, USA
    J Leukoc Biol 80:1262-71. 2006
    ..These findings are relevant for the development of a vaccine administered in regions with elevated levels of environmental mycobacteria...
  86. ncbi Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice
    Li Mei Wang
    Department of Microbiology, Fourth Military Medical University, Xi an 710032, China
    Chin Med J (Engl) 120:1220-5. 2007
    ..Thus, developing new tuberculosis vaccines becomes an urgent task. In this study, we evaluated in BALB/c mice the humoral and cellular immune responses of recombinant BCG expressing the antigen ESAT-6 from Mycobacterium tuberculosis...
  87. ncbi CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo
    Siobhán C Cowley
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research Food and Drug Administration, Rockville, MD 20852, USA
    J Immunol 171:4689-99. 2003
    ..These findings demonstrate that CD4(+) T cells possess IFN-gamma-independent mechanisms that can limit the growth of an intracellular pathogen and are dominant in secondary responses to M. tuberculosis...
  88. ncbi Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
    In previous studies, we have described a live recombinant BCG vaccine (rBCG30) overexpressing the 30 kDa major secretory protein of Mycobacterium tuberculosis that induces greater protective immunity against tuberculosis than the current ..
  89. ncbi Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?
    Graham A W Rook
    Centre for Infectious Disease and International Health, University College London, Windeyer Institute of Medical Sciences, London W1T 4JF, UK
    Vaccine 23:2115-20. 2005
    ..A successful vaccine, rather than driving a Th1 response, might need to suppress this pre-existing subversive Th2-like component...
  90. ncbi Influence of BCG vaccine strain on the immune response and protection against tuberculosis
    Nicole Ritz
    Department of Paediatrics, The University of Melbourne, Australia
    FEMS Microbiol Rev 32:821-41. 2008
    ..The recent delineation of genetic differences between BCG vaccine strains has renewed interest in the influence of the vaccine strain on the protective efficacy against ..
  91. pmc HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 199:982-90. 2009
    ..Information regarding the immunogenicity of BCG is imperative for the risk/benefit assessment of BCG vaccination in HIV-infected infants; however, no such data exist...
  92. ncbi Mycobacterium bovis BCG vaccination induces memory CD4+ T cells characterized by effector biomarker expression and anti-mycobacterial activity
    Janice J Endsley
    Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, United States
    Vaccine 25:8384-94. 2007
    ....
  93. pmc Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  94. ncbi Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression
    A Bohle
    HELIOS Agnes Karll Hospital, Bad Schwartau, Germany
    Urology 63:682-6; discussion 686-7. 2004
    ..To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on progression of Stage Ta and T1 bladder carcinoma...
  95. ncbi Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis
    Florian Winau
    Department of Immunology, Max Planck Institute for Infection Biology, Schumannstrasse 21 22, 10117 Berlin, Germany
    Immunity 24:105-17. 2006
    ..tuberculosis infection. Taken together, we propose the detour pathway to represent a genuine immunological mechanism mediating crosspriming of CD8 T cells in vivo and protection against tuberculosis...
  96. ncbi Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  97. ncbi Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity
    Xinan Jiao
    Unité de Biologie des Régulations Immunitaires, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
    J Immunol 168:1294-301. 2002
    ..Strikingly, BCG bacilli survive but remain stable in number in the DC leukocyte subset during the first 2 wk of infection. As Ag presentation by DC is rapidly lost, this suggests that DC may represent a hidden reservoir for mycobacteria...
  98. ncbi Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis
    F E Aldwell
    Department of Microbiology and Immunology, University of Otago, P O Box 56, Dunedin, New Zealand
    Vaccine 24:2071-8. 2006
    ....
  99. pmc Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis
    M Singh
    Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Arch Dis Child 90:624-8. 2005
    ..To study the prevalence of tuberculosis infection among children in household contact with adults having pulmonary tuberculosis, and identify the possible risk factors...
  100. ncbi Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells
    Chinnaswamy Jagannath
    Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center UTHSC, 6431, Fannin, Houston, Texas 77030, USA
    Nat Med 15:267-76. 2009
    ..Finally, overexpression of Ag85B in BCG induced autophagy in APCs and enhanced immunogenicity in mice, suggesting that vaccine efficacy can be enhanced by augmenting autophagy-mediated antigen presentation...
  101. ncbi Ascertainment of childhood vaccination histories in northern Malawi
    A Jahn
    Karonga Prevention Study, Chilumba, Malawi
    Trop Med Int Health 13:129-38. 2008
    ..To assess factors related to recorded vaccine uptake, which may confound the evaluation of vaccine impact...

Research Grants62

  1. Effect Ultraviolet Radiation on Latent M. tuberculosis Infection in Guinea Pigs
    Amminikutty Jeevan; Fiscal Year: 2010
    ..bovis BCG is the only vaccine currently available for the prevention of tuberculosis;however, the efficacy of BCG vaccine has been highly variable in clinical trials...
  2. Crystalline Endolysin Treatment for Tuberculosis in TB/HIV co-infected patients
    BHAMI C SHENOY; Fiscal Year: 2012
    ..As a preventive measure, currently BCG vaccine is used to avoid serious complications of TB and to reduce the rate of pediatric TB but It has little or no ..
  3. Expression signatures of TB-specific memory responses within the human lung
    Richard F Silver; Fiscal Year: 2013
    ..the mechanisms by which cell recruitment enhances containment of Mtb within the lungs of both LTBI subjects and BCG vaccine recipients...
  4. Novel Bacillus subtilis based spore vaccine to tuberculosis
    Subramanian Dhandayuthapani; Fiscal Year: 2013
    ..a potential for this to be a prophylactic vaccine replacement for BCG, and a booster vaccine for those who had BCG vaccine earlier but with no protective immune response...
  5. Systems Biology for Molecular Analysis of Tuberculosis in Ethiopia
    Gobena Ameni; Fiscal Year: 2013
    ..This proposal includes innovative systems biology research as well as a program training Ethiopian scientists in genomics disciplines and applications to infectious diseases. 2. ..
  6. Synthesis of Novel Bioactive Sphingolipids as a Resource
    Robert Bittman; Fiscal Year: 2013
    ..The uses of the compounds include developing new approaches for prevention of pulmonary arterial hypertension, lung inflammation, and pulmonary infection from Mycobacterium tuberculosis...
  7. Macaque model of TB/AIDS co-infection via natural routes of exposure
    Deepak Kaushal; Fiscal Year: 2010
    ..2. Determine if rhesus macaques latently infected with low-dose aerosols of Mtb reactivate to active disease in a significantly different fashion, following intravenous SIV infection. ..
  8. Tuberculosis Immunization to Prevent Infection (TIPI)
    Edward A Nardell; Fiscal Year: 2013
    ..to plan over a one-year period a prospective, open-label, randomized controlled trial of a currently available BCG vaccine to prevent primary M. tuberculosis infection...
  9. Pro-Apoptotic BCG as an HCV vaccine vector
    Spyros A Kalams; Fiscal Year: 2010
    ..The modified BCG vaccine, called "pro-apoptotic BCG", demonstrates potent immune responses in susceptible mouse strains...
  10. Pre-Exposure Prophylaxis Against Francisella tularensis
    MARCUS AARON HORWITZ; Fiscal Year: 2013
    ..laboratory to develop the first vaccines against tuberculosis that are safer and more potent than the current BCG vaccine;one of these tuberculosis vaccines has already demonstrated safety and enhanced immunogenicity in human trials...
  11. Generation and Evaluation of Pro-Apoptotic rBCG and Viral Vectors as TB Vaccine C
    Thomas Evans; Fiscal Year: 2012
    ..An increasingly well documented defect in the BCG vaccine lies in its inability to escape the phagolysosome of infected macrophages and dendritic cells, which, unlike M...
  12. Diagnostic yield of induced sputum for rapid diagnosis of pulmonary tuberculosis
    Mark Hatherill; Fiscal Year: 2011
    ..We have successfully used this technique to investigate over 1,800 children in a Phase IV BCG vaccine trial...
  13. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2013
    ..More people die of tuberculosis each year than due to other diseases. The available BCG vaccine is partially protective against children and is not effective against adult disease...
  14. Lactoferrin as an Adjuvant for Cellular Immunity
    Jeffrey K Actor; Fiscal Year: 2010
    ..proposal are to utilize fully humanized recombinant lactoferrin (rhLF) as an adjuvant to enhance the BCG vaccine to strengthen host defense against subsequent mycobacterial infection, and to limit pathogen induced tissue ..
  15. Pre-Exposure Prophylaxis Against Francisella tularensis
    MARCUS AARON HORWITZ; Fiscal Year: 2012
    ..laboratory to develop the first vaccines against tuberculosis that are safer and more potent than the current BCG vaccine;one of these tuberculosis vaccines has already demonstrated safety and enhanced immunogenicity in human trials...
  16. A Community Mycobacterial Systems Resource
    JOSEPH THOMAS WADE; Fiscal Year: 2013
    ..This global crisis is exacerbated by inadequate treatments: the BCG vaccine is of questionable efficacy, and the incidence of multi-drug and extremely-drug resistant strains of M...
  17. OPIATE MODULATION OF PULMONARY INFECTION
    Thomas Molitor; Fiscal Year: 2000
    ..HIV infection, foster the development of disseminated TB, whereas immunization with Mycobacterium bovis BCG vaccine confers protection against dissemination to the CNS...
  18. GENETIC VACCINE FOR MYCOBACTERIUM TUBERCULOSIS
    Stephen Johnston; Fiscal Year: 2000
    ..The ELI approach may provide a new and rapid method for developing a Mtb vaccine as well as for other emerging pathogens. ..
  19. IN VIVO IMMUNE ACTIVATION/ FIV GENE EXPRESSION
    Satya Dandekar; Fiscal Year: 1992
    ....
  20. IMPROVED VACCINIA RECOMBINANTS FOR TUBERCULOSIS VACCINE
    Anthony Coates; Fiscal Year: 1991
    A new vaccine for tuberculosis is required. Although the existing, live Mycobacterium bovis BCG vaccine protects children against tuberculosis in many countries, it causes side-effects, such as fatal disseminated disease in ..
  21. Laboratory Syntheses of Mycobacterial tuberculosis LAM Prototypes
    BERTRAM OLIVER FRASER REID; Fiscal Year: 2010
    ..The BCG vaccine that worked so well for decades is no longer reliable...
  22. Enhancement of Tuberculosis Vaccine by Thymosin
    Cynthia Tuthill; Fiscal Year: 2003
    ..Although most of the earths' 5.7 billion inhabitants have received the attenuated M. bovis BCG vaccine, many have still become infected and are at risk for developing clinical disease...
  23. Novel Delivery of a New Vaccine for Tuberculosis
    DIANE PEREIRA; Fiscal Year: 2003
    ..The current vaccine for tuberculosis is the BCG vaccine. BCG has been proven safe and effective at protecting young children, it is relatively inexpensive to produce, ..
  24. Mycobacteria interactions and vaccine efficacy
    Joanne Turner; Fiscal Year: 2004
    ..EM] is believed to be the primary mechanism thought to be responsible for the reduced efficacy of the BCG vaccine against tuberculosis in many parts of the world...
  25. Tubercle Bacilli Binding to Host Cells: Vaccine Design
    Luanne Hall Stoodley; Fiscal Year: 2002
    ..die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB are needed...
  26. X RAY STUDIES OF PROTEIN ANTIGENS OF M TUBERCULOSIS
    NAND VYAS; Fiscal Year: 1999
    ..These objectives are justified because currently used diagnostic reagents and the BCG vaccine are not very reliable...
  27. MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS
    William Jacobs; Fiscal Year: 1991
    ..coli-mycobacteria shuttle vector, we have introduced recombinant DNA molecules into both M. smegmatis and BCG vaccine strains for the first time...
  28. Mechanistic Studies at the Host-pathogen Interface
    David McMurray; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  29. DIETARY DEFICIENCIES AND TUBERCULOSIS VACCINE EFFICACY
    David McMurray; Fiscal Year: 2009
    ..abstract_text> ..
  30. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  31. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  32. M TUBERCULOSIS PHAGOSOME
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis to survive and multiply within its host cells and should facilitate the development of new strategies for prevention and treatment of tuberculosis. ..
  33. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  34. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2008
    ..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
  35. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
    ..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. [unreadable] [unreadable]..
  36. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..This vaccine, named rBCG30, is a live recombinant BCG vaccine expressing the M. tuberculosis 30 kDa major secretory protein...
  37. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
  38. Characterization of the Francisella tularensis phagosome
    MARCUS HORWITZ; Fiscal Year: 2003
    ..tularensis subverts the host cell membrane trafficking pathways and attains an intracellular compartment that is hospitable for its survival and growth will help guide new strategies for the prevention and treatment of tularemia. ..
  39. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  40. BCG in Endogeneous and Exogenous Antigen-Induced T Cell
    Yi Luo; Fiscal Year: 2005
    ..abstract_text> ..
  41. Therapeutic Targeting Agents for Bladder Cancer
    Yi Luo; Fiscal Year: 2005
    ..abstract_text> ..
  42. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  43. Guinea pig model for TB vaccine evaluations
    Ian Orme; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  44. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..work to determine the basis of down-regulation in vaccination, specifically in terms of interference with the BCG vaccine; and [4] the nature and antigenic targets of the CD8 T cell response in the lungs and the potential for CD8-..
  45. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  46. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  47. Metabolism of M. tuberculosis: New Targets for MDR TB
    David Russell; Fiscal Year: 2004
    ..abstract_text> ..
  48. GLYOXYLATE SHUNT AND PARASITISM BY MYCOBACTERIUM SPP
    David Russell; Fiscal Year: 2004
    ..We will use the recombinant enzymes to screen drug libraries at GlaxoWellcome. Structural information generated by Dr. Sacchettini will be central to the development of effective inhibitors against these enzymes. ..
  49. IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
    Paul Chapman; Fiscal Year: 2003
    ..The specific aims for the GD3 system are: a) To determine the relative immunogenicity of BEC2/BCG vaccine at a range of BEC2 doses; b) To determine whether prolonged immunization with BEC2 boosts the anti-GD3 antibody ..
  50. TRANSMISSION DYNAMICS OF TB ALONG THE U.S.-MEXICO BORDER
    Peter Barnes; Fiscal Year: 2004
    ..Finally, it will determine if rapid RFLP methods can contribute to TB control efforts. The knowledge gained will permit refinement of TB control strategies along the U.S.-Mexico border and in Latin America. ..
  51. AUTOLOGOUS HAPTEN MODIFIED VACCINE FOR HUMAN CANCER
    David Berd; Fiscal Year: 2001
    ..This work may lead to the development of reagents useful in identifying the target antigens. ..
  52. Development of a Novel Strategy of Adjuvant Discovery
    David Russell; Fiscal Year: 2009
    ..It is anticipated that this final aim will develop into a new grant application that will enable us to test the effectiveness of a range of microbial products for their efficacy as adjuvants. ..
  53. Th1-to Th2 shift of HSP65 responses and atherogenesis
    Yoshimi Shibata; Fiscal Year: 2005
    ..Finally, we will determine if transfusion of fit-1 +marrow cells from HK-BCG treated WT donors will restore the Thl-to-Th2 shifts in 89Sr-treated WT recipients. ..
  54. Reactivation Tuberculosis in A/J
    Chinnaswamy Jagannath; Fiscal Year: 2005
    ..These studies are anticipated to enhance our understanding on putative mechanisms that precede the reactivation of tuberculosis in the lungs of mice and ultimately help us to develop better strategies to prevent tuberculosis in man. ..
  55. Regulation of IFN-gamma production in human tuberculosis
    Peter Barnes; Fiscal Year: 2009
    ..CREB/ATF/AP-1 levels in T-cells of tuberculosis patients will be enhanced by viral expression vectors and nucleofection, and the effects on IFN-gamma production will be determined. ..
  56. Phase II trial of 17-AAG in melanoma patients
    Paul Chapman; Fiscal Year: 2007
    ..post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. [unreadable] [unreadable] [unreadable]..
  57. Zeiss LSM510 Meta Confocal Microscope
    David Russell; Fiscal Year: 2007
    ..These data will extend ongoing, NIH-funded programs for identification of new drug targets, vaccines and adjuvants. [unreadable] [unreadable] [unreadable]..
  58. Cell Biology of Mycobacterium tuberculosis Infection
    David G Russell; Fiscal Year: 2010
    ..tuberculosis. We propose determining how the bacterium's metabolism is realigned to access these carbon sources. ..
  59. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2006
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. [unreadable] [unreadable]..
  60. Alternative endpoints for plague challenge models
    Richard Frothingham; Fiscal Year: 2005
    ..We will use the data generated to refine our hypotheses and to pursue further funding to complete Aim 3. ..
  61. Chemoprevention of murine urinary bladder carcinogenesis
    Ashish Kamat; Fiscal Year: 2005
    ..abstract_text> ..
  62. FLAGELLAR POCKET OF LEISHMANIA
    David Russell; Fiscal Year: 2001
    ..abstract_text> ..